In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis.

MLA

Galluzzo, Marco, et al. “In Which Patients the Best Efficacy of Secukinumab? Update of a Real-Life Analysis after 136 Weeks of Treatment with Secukinumab in Moderate-to-Severe Plaque Psoriasis.” Expert Opinion on Biological Therapy, vol. 20, no. 2, Feb. 2020, pp. 173–82. EBSCOhost, https://doi.org/10.1080/14712598.2020.1708897.

APA

Galluzzo, M., D’Adamio, S., Silvaggio, D., Lombardo, P., Bianchi, L., & Talamonti, M. (2020). In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opinion on Biological Therapy, 20(2), 173–182. https://doi.org/10.1080/14712598.2020.1708897

Chicago

Galluzzo, Marco, Simone D’Adamio, Dionisio Silvaggio, Paolo Lombardo, Luca Bianchi, and Marina Talamonti. 2020. “In Which Patients the Best Efficacy of Secukinumab? Update of a Real-Life Analysis after 136 Weeks of Treatment with Secukinumab in Moderate-to-Severe Plaque Psoriasis.” Expert Opinion on Biological Therapy 20 (2): 173–82. doi:10.1080/14712598.2020.1708897.